A detailed history of Great West Life Assurance CO transactions in Bio N Tech Se stock. As of the latest transaction made, Great West Life Assurance CO holds 4,766 shares of BNTX stock, worth $575,542. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,766
Previous 4,606 3.47%
Holding current value
$575,542
Previous $370,000 52.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$78.36 - $124.66 $12,537 - $19,945
160 Added 3.47%
4,766 $566,000
Q2 2024

Aug 12, 2024

BUY
$80.36 - $102.87 $94,824 - $121,386
1,180 Added 34.44%
4,606 $370,000
Q1 2024

May 13, 2024

BUY
$88.96 - $112.35 $135,041 - $170,547
1,518 Added 79.56%
3,426 $316,000
Q4 2023

Feb 13, 2024

SELL
$90.91 - $112.75 $78,182 - $96,965
-860 Reduced 31.07%
1,908 $200,000
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $176,019 - $223,517
1,787 Added 182.16%
2,768 $302,000
Q2 2023

Aug 10, 2023

SELL
$102.58 - $129.66 $718 - $907
-7 Reduced 0.71%
981 $106,000
Q1 2023

May 12, 2023

BUY
$122.57 - $153.67 $56,872 - $71,302
464 Added 88.55%
988 $123,000
Q4 2022

Feb 10, 2023

BUY
$118.43 - $186.05 $7,105 - $11,163
60 Added 12.93%
524 $79,000
Q3 2022

Nov 01, 2022

BUY
$127.65 - $183.11 $59,229 - $84,963
464 New
464 $62,000
Q2 2022

Aug 09, 2022

SELL
$123.25 - $186.24 $200,034 - $302,267
-1,623 Reduced 79.52%
418 $62,000
Q1 2022

May 12, 2022

BUY
$126.25 - $231.85 $216,266 - $397,159
1,713 Added 522.26%
2,041 $371,000
Q4 2021

Feb 14, 2022

BUY
$216.64 - $362.52 $9,532 - $15,950
44 Added 15.49%
328 $84,000
Q3 2021

Nov 15, 2021

BUY
$205.93 - $447.23 $58,484 - $127,013
284 New
284 $78,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $29.3B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.